AI-Guided Cardiac Ablation Outperforms Standard Treatment for Persistent Atrial Fibrillation

The TAILORED-AF clinical trial, published in Nature Medicine, demonstrated superior outcomes for AI-guided cardiac ablation compared to conventional pulmonary vein isolation (PVI) alone in treating persistent atrial fibrillation124.

88% of patients in the AI-guided group experienced freedom from atrial fibrillation 12 months after one procedure, compared to 70% in the conventional treatment group124.

The study enrolled 370 patients across 26 centers in 5 countries, with 187 receiving AI-guided ablation and 183 receiving conventional PVI treatment124.

Volta Medical's AF-Xplorer, an AI-based digital companion, was used to assist cardiologists in real-time identification of abnormal electrograms during the procedure12.

The trial is the first large-scale international randomized controlled trial in interventional cardiology to demonstrate superior efficacy through the use of AI46.

Patients in the AI-guided group also experienced a higher rate of freedom from any arrhythmia after 1.2 procedures (79% vs. 71%)24.

The safety endpoint did not differ between groups, although procedure and ablation times were longer in the AI-guided arm12.

This study represents a significant advancement in treating persistent atrial fibrillation, which affects over 70% of all atrial fibrillation patients globally46.

Sources:

1. https://www.massdevice.com/volta-medical-data-ai-ablation-afib/

2. https://cardiacrhythmnews.com/volta-medicals-ai-guided-cardiac-ablation-procedure-found-to-improve-af-treatments/

4. https://www.globenewswire.com/news-release/2025/02/14/3026511/0/en/Volta-Medical-Artificial-Intelligence-guided-Cardiac-Ablation-Procedure-Improves-Treatment-of-Atrial-Fibrillation.html

6. https://www.volta-medical.us/press-releases/ai-guided-cardiac-ablation-procedure-improves-afib-treatment